Valuation : Orion Oyj

Market Cap 11.23B 13.05B 10.57B 9.65B 18.06B 1,232B 18.11B 125B 48.46B 632B 49.01B 47.94B 2,037B P/E 2026 *
19.8x
P/E 2027 * 16.8x
Enterprise Value 11.14B 12.95B 10.48B 9.58B 17.91B 1,223B 17.96B 124B 48.07B 627B 48.62B 47.56B 2,021B EV / Sales 2026 *
5.31x
EV / Sales 2027 * 4.59x
Free-Float
90.5%
Yield 2026 *
2.44%
Yield 2027 * 2.72%
1 day+4.81%
6 months+4.81%
Current year+1.78%
Current year 78.95
Extreme 78.95
82.75
1 year 78.95
Extreme 78.95
82.75
3 years 37.44
Extreme 37.44
82.75
5 years 37
Extreme 37
82.75
10 years 27.35
Extreme 27.35
82.75
Manager TitleAgeSince
Chief Executive Officer 59 2022-10-31
Director of Finance/CFO 50 2024-04-30
Chief Operating Officer 46 2021-12-31
Director TitleAgeSince
Director/Board Member 63 2017-03-21
Director/Board Member 65 2017-03-21
Director/Board Member 66 2020-05-05
Change 5-day change 1-year change 3-year change Capi.($)
+4.81%-.--% - - 13.05B
-0.88%-2.15%+58.05%+105.91% 1,024B
-1.15%+2.68%+54.25%+71.29% 663B
-1.44%+0.38%+20.65%+75.54% 453B
+0.14%-0.47%+30.20%+40.61% 352B
-1.33%+4.72%+24.62%+47.60% 304B
-1.15%+0.30%-0.69%+11.83% 252B
-1.55%+1.11%+54.15%+72.13% 236B
-0.88%+1.15%-14.60%-54.84% 206B
-0.15%+3.65%+31.24%+100.90% 187B
Average -0.36%+1.09%+28.65%+52.33% 408.71B
Weighted average by Cap. -0.94%+0.55%+37.63%+67.00%

Financials

2026 *2027 *
Net sales 2.1B 2.44B 1.97B 1.8B 3.37B 230B 3.38B 23.32B 9.05B 118B 9.15B 8.95B 380B 2.37B 2.76B 2.23B 2.04B 3.82B 260B 3.83B 26.39B 10.24B 134B 10.36B 10.13B 430B
Net income 566M 658M 532M 486M 910M 62.09B 912M 6.29B 2.44B 31.86B 2.47B 2.42B 103B 668M 776M 628M 574M 1.07B 73.29B 1.08B 7.43B 2.88B 37.6B 2.91B 2.85B 121B
Net Debt -89.76M -104M -84.45M -77.15M -144M -9.85B -145M -998M -387M -5.05B -392M -383M -16.28B -333M -387M -313M -286M -535M -36.53B -537M -3.7B -1.44B -18.74B -1.45B -1.42B -60.38B
Logo Orion Oyj
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows: - innovative medicines (43%): for the treatment of cancer and pain management; - generic, OTC and biosimilar drugs (29.3%); - branded prescription products (16.6%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments; - veterinary products (7.5%); - pharmaceutical ingredients and outsourcing services (3.6%). Net sales break down primarily by source of revenue between sales of products (67.2%) and royalties (23.1%). Net sales are distributed geographically as follows: Finland (19.3%), Scandinavia (10%), Europe (28.1%), North America (25.5%) and other (17.1%).
Employees
4,000
Date Price Change Volume
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
79.80EUR
Average target price
76.67EUR
Spread / Average Target
-3.93%

Quarterly revenue - Rate of surprise